Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
$0.06
+5.0%
$0.07
$0.05
$0.15
$7.51M1.4511,613 shs16,216 shs
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$1.45
$1.47
$0.97
$19.44
$8.07M1.46449,302 shs115,413 shs
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$0.37
+0.9%
$0.35
$0.29
$2.69
$8.37M1.35279,212 shs59,751 shs
VGLS
VG Life Sciences
$0.00
$0.00
$0.00
$0.00
N/A1.677.16 million shs7.50 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
+5.00%+0.33%-6.16%+10.33%-49.25%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
+1.40%-2.03%-12.12%-16.67%+144,999,900.00%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
+0.86%+1.70%+1.14%+1.14%-83.70%
VGLS
VG Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.1992 of 5 stars
0.02.00.00.01.90.80.0
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
1.199 of 5 stars
1.83.00.00.00.02.51.3
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.00
N/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
0.00
N/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
1.50
Reduce$0.4523.25% Upside
VGLS
VG Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/A($0.04) per shareN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
$230K35.05N/AN/A($8.66) per share-0.17
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/AN/AN/AN/A$1.36 per shareN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
-$2.55M-$0.01N/AN/AN/AN/A-609.07%9/23/2025 (Estimated)
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$166.52M-$32.81N/AN/AN/A-15,245.81%N/A-193.21%8/21/2025 (Estimated)
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$70.84M-$2.73N/AN/AN/AN/A-162.79%-124.10%8/13/2025 (Estimated)
VGLS
VG Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A

Latest VGLS, BETRF, TRAW, and TSBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
-$8.04$2.09+$10.13$2.09$0.06 million$0.06 million
5/8/2025Q1 2025
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.26-$0.51-$0.25-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/AN/A
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/AN/AN/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/A
0.04
0.04
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
N/A
1.81
1.81
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/A
3.70
3.70
VGLS
VG Life Sciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.01%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
7.95%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
52.51%
VGLS
VG Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
34.77%
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
13.60%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
32.10%
VGLS
VG Life Sciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
7129.46 million84.45 millionNot Optionable
Traws Pharma, Inc. stock logo
TRAW
Traws Pharma
175.56 million4.81 millionOptionable
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
8223.14 million15.71 millionNot Optionable
VGLS
VG Life Sciences
121.10 billionN/ANot Optionable

Recent News About These Companies

VGLS VG Life Sciences Inc. - Seeking Alpha
VG Life Sciences Inc.
VG Life Sciences, Inc. Increases Authorized Shares
VG Life Sciences Inc. (VGLS)
VG Life Sciences Inc VGLS
Report warns of 'oversupply' of life sciences real estate
VGLS VG Life Sciences Inc.

Media Sentiment Over Time

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:BETRF

$0.06 +0.00 (+5.00%)
As of 07/7/2025 10:03 AM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Traws Pharma stock logo

Traws Pharma NASDAQ:TRAW

$1.45 0.00 (0.00%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$1.44 -0.01 (-0.69%)
As of 07/7/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Turnstone Biologics stock logo

Turnstone Biologics NASDAQ:TSBX

$0.37 +0.00 (+0.91%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.85%)
As of 07/7/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)
As of 07/7/2025 02:04 PM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.